Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126336722 | 12633672 | 2 | F | 20160815 | 20160808 | 20160822 | EXP | PHHY2016BR108680 | NOVARTIS | 0.00 | M | Y | 0.00000 | 20160822 | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126336722 | 12633672 | 1 | PS | TASIGNA | NILOTINIB | 1 | Oral | 200 MG, QID | 22068 | 200 | MG | CAPSULE | QID | ||||||
| 126336722 | 12633672 | 2 | C | EUTHYROX | LEVOTHYROXINE SODIUM | 1 | Oral | 1 DF, QD | 0 | 1 | DF | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126336722 | 12633672 | 1 | Chronic myeloid leukaemia |
| 126336722 | 12633672 | 2 | Thyroid disorder |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126336722 | 12633672 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126336722 | 12633672 | Abdominal pain | |
| 126336722 | 12633672 | Blood glucose increased | |
| 126336722 | 12633672 | Dry skin | |
| 126336722 | 12633672 | Dysphonia | |
| 126336722 | 12633672 | Food interaction | |
| 126336722 | 12633672 | Incorrect drug administration duration |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |